BONESUPPORT: Increasing conviction, PT raised to SEK400

BONESUPPORT trades at a premium on EV/Sales and EV/EBITDA to peers, yet a valuation justified by its unique market positioning. The company leads the ortho-biologics market without competition for its antibiotic-eluting CERAMENT products. Beyond its proprietary technology, BONESUPPORT consistently

Bonesupport Holding AB: 1 director

A director at Bonesupport Holding AB sold 59,407 shares at 325.000SEK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Growth case confirmed

Strong sales growth in the US

BONESUPPORT: CERAMENT G leads strong US growth amid softer EU seasonal...

Q3 2024 followed a similar trend to the first half of the year, with CERAMENT G leading revenue generation. Exceeding expectations, CERAMENT G grew by SEK 25m QoQ in the US, reaching SEK 132m, as the company rapidly secures new hospital agreements. However, CERAMENT BVF saw a slight decline, with U

CERAMENT G to drive growth in Q3

BONESUPPORT: SOLARIO study results signal a paradigm shift in osteomye...

At the EBJIS 2024 conference, we had the pleasure of hearing firsthand the remarkable top-line SOLARIO study results presented by Prof. Martin McNally, a well-known KOL in the bone infection industry. Involving 500 patients with orthopaedics infections, with 1-year follow-up, the study aimed at ass

Positive top-line data from SOLARIO

Positive US hospital capex outlook for H2'24

Small Cap Miner – August 2024

US expansion continues

Stellar growth in the US

BONESUPPORT: Stellar Q2 results, raise 2024 sales guidance to >50% gro...

Q2 2024 earnings continued the positive growth trajectory in all geographies and BONEX products, leading the company to raise its guidance for 2024 with a sales growth of over 50% (BG estimates stand at 50% ). Importantly CERAMENT G sales overpassed the SEK 100m threshold in the US for the first ti

US growth expected to shine in Q2

Expect another quarter with strong growth. EBIT down 1.0-1.9% due to FX. Q2'24 results due 11 July.

BONESUPPORT: CERAMENT V to enter the US in Q2 2025 instead of H2

Yesterday, during trading hours, BONESUPPORT announced that CERAMENT V will follow the 510(k) FDA path instead of De Novo, positively shortening the time to market to Q2 2025 instead of YE 2025. Such a decision coming from the FDA is backed by the fact that CERAMENT V (vancomycin), despite having a

Small Cap Miner - May 2024

Impressive earnings beat in Q1

Confirmation of the growth case. '24e EBIT revised up +8%. BUY and TP of SEK 310 maintained.

BONESUPPORT: debuts 2024 with strong financial results

Q1 2024 sales climbed by 54% (54% at CER) YoY and 7% QoQ, totalling SEK 184.4m. The US market, owing 77% of overall sales, was boosted by a 65% growth (65% at CER), with CERAMENT G being the major driver bringing SEK 92m sales (SEK 34.8m). EU showed a 27% YoY growth in sales, delivered by both prod

Strong start in Q1

BONESUPPORT: CERAMENT doubles US TAM, on track to reach >SEK 2bn sales...

BONESUPPORT share price climbed by ~8% yesterday as of the FDA approval of CERAMENT G in open fracture/trauma following the 510(k) submission in Q4 2023. Although our estimates were aligned with the positive FDA outcome, we find it worth highlighting the impressive growth path behind and refreshing